Preclinical safety and efficacy of the NeVa NET™: A novel thrombectomy device with integrated embolic distal protection Preclinical safety and efficacy of the NeVa NET™

Main Article Content

Vania Anagnostakou
Raul G Nogueira
Mark Epshtein
Matthew J Gounis
Daniel Behme
Arthur Ulm
Rishi Gupta

Abstract

Background


High quality reperfusion is linked to better clinical outcomes during thrombectomy for large vessel occlusion in acute ischemic stroke. A novel stent-retriever device with an integrated microfilter for embolic distal protection has been developed to improve first pass full reperfusion.


Objective


Compare the safety and effectiveness of the NeVa NET versus the standard stent-retriever thrombectomy devices.


Materials and methods


Radial force measurements were performed on 10 NeVa NET™ and 4 Solitaire™ 6x30mm. Animal studies involving three Yorkshire pigs were performed comparing NeVa NET™ to Solitaire™ 6x40mm and 4x40mm to assess for acute vascular injury, vasospasm and thrombogenicity during thrombectomy. A randomized comparison in a closed loop vascular model was performed to quantify first pass effect and distal emboli generated during twenty MCA thrombectomies.


Results


Radial force curves were similar between the NeVa NET™ and Solitaire™ 6x30mm. Below 2.5mm the Solitaire™ demonstrated higher radial force compared to NeVa NET™. Vasospasm scores were nearly identical after four thrombectomies in multiple similar sized swine arteries. The addition of the internal filter did not result in increased thrombogenicity in the non-heparinized swine model. In the randomized flow model study, NeVa NET™ required less passes than Solitaire™ to achieve TICI 3 reperfusion (p=0.0344). Solitaire™ generated 4-fold more clot fragments >1mm in size compared to NeVa Net™ (p=0.037, Wilcoxan rank sum). For fragments between 0.2-1mm, Solitaire™ generated 91 whereas NeVa™ generated a total of 20 fragments. Overall, more clot fragments were generated during Solitaire™ as compared to NeVa NET™ thrombectomy (p=0.048). 


Conclusions


Our pre-clinical results support the use of the NeVa NETTM device in a clinical trial to determine if this novel design improves first pass full reperfusion. 

Downloads

Download data is not yet available.

Article Details

How to Cite
Anagnostakou, V., Nogueira, R. G., Epshtein, M., Gounis, M. J., Behme, D., Ulm, A., & Gupta, R. (2023). Preclinical safety and efficacy of the NeVa NET™: A novel thrombectomy device with integrated embolic distal protection: Preclinical safety and efficacy of the NeVa NET™. Journal of Vascular and Interventional Neurology, 14(2), 1–16. Retrieved from https://ojs.jvin.org/index.php/jvin/article/view/18
Section
Original research article